OVCaR-3

By Targets:	Antibody-Drug Conjugates (ADCs) (2) Apoptosis (5) Caspase (1) CDK (3) Drug Metabolite (1) Epigenetic Reader Domain (1) Ferroptosis (1) Histone Acetyltransferase (1) MDM-2/p53 (1) Microtubule/Tubulin (5) PARP (1) Raf (1) Ras (1) Reactive Oxygen Species (1) ROS Kinase (1)
By Research Areas:	Cancer (19)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N3558

Ceanothic acid Emmolic acid	Others	Cancer
Ceanothic acid (Emmolic acid) is a ring-A homologue of betulinic acid. Ceanothic acid inhibits OVCAR-3, HeLa, and FS-5 cells with the cell survival of 68%, 65%, and 81%, respectively .

HY-145389

SZ-015268	CDK	Cancer
SZ-015268 is a CDK7 inhibitor with an IC₅₀ of 23.56 nM. SZ-015268 has extremely significant anti-tumor advantages. SZ-015268 inhibits HCC70, OVCAR-3, HCT116 and HCC1806 cells proliferation with IC₅₀s of 33, 80.56, 12.53, and 61.55 nM, respectively .

HY-143339

CBP/p300-IN-15	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-15 (compound 13a) is a potent p300/CBP inhibitor, with IC₅₀ values of 2.50 and 28.0 nM, respectively. CBP/p300-IN-15 shows good activity against OVCAR-3 and A2780 cell line, with EC₅₀ values of 0.865 and 2.71 μM, respectively. CBP/p300-IN-15 can be used for ovarian cancer research .

HY-N7760

Neosalvianen	Others	Others
Neosalvianen is a N-containing compound that shows cytotoxic activities against the HeLa, HepG2, and OVCAR-3 cell lines, with IC₅₀ of 63.9 µM, 59.2 µM, and 74.6 µM, respectively .

HY-N10268

3-Hydroxyterphenyllin NSC 299113	Apoptosis	Cancer
3-Hydroxyterphenyllin is a metabolite of Aspergillus candidus.3-Hydroxyterphenyllin suppresses proliferation and causes cytotoxicity against A2780/CP70 and OVCAR-3 cells. 3-Hydroxyterphenyllin induces S phase arrest and apoptosis. 3-Hydroxyterphenyllin has the potential for the research of ovarian cancer .

HY-155966

CDK2-IN-19

CDK Cancer

CDK2-IN-19 (Compound 32) is a selective and orally active CDK2 inhibitor (K_i: 0.18 nM). CDK2-IN-19 shows anticancer activity in mice bearing OVCAR3 tumors .

CDK2-IN-19	CDK	Cancer
CDK2-IN-19 (Compound 32) is a selective and orally active CDK2 inhibitor (K_i: 0.18 nM). CDK2-IN-19 shows anticancer activity in mice bearing OVCAR3 tumors .

HY-153221

QR-6401	CDK	Cancer
QR-6401 is an orally active and selective macrocyclic CDK2 inhibitor with IC₅₀ values of 0.37, 10, 22, 34 and 45 nM for CDK2/E1, CDK9/T1, CDK1/A2, *CDK6/D3* and CDK4/D1, respectively. QR-6401 has potent antitumor activity in an OVCAR3 ovarian cancer xenograft model. QR-6401 has the potential to be used in the study of cancer .

HY-N10922

(3S,4aS,10aS)-3-(Acetyloxy)-2,3,4,4a,10,10a-hexahydro-6-hydroxy-1,1,4a-trimethyl-7-(1-methylethyl)-9(1H)-phenanthrenone	Others	Cancer
(3S,4aS,10aS)-3-(Acetyloxy)-2,3,4,4a,10,10a-hexahydro-6-hydroxy-1,1,4a-trimethyl-7-(1-methylethyl)-9(1H)-phenanthrenone (compound 3), a Palmitate, can be isolated from the root tissue of Salvia miltiorrhiza. (3S,4aS,10aS)-3-(Acetyloxy)-2,3,4,4a,10,10a-hexahydro-6-hydroxy-1,1,4a-trimethyl-7-(1-methylethyl)-9(1H)-phenanthrenone (compound 3) shows anti-cancer activity against human cancer cell lines with DC₅₀s of 25.5 μg/mL (HeLa), 37.5 μg/mL (HepG2), 30.2 μg/mL (OVCAR-3), respectively .

HY-132840

Sovilnesib AMG 650	Microtubule/Tubulin	Cancer
Sovilnesib (AMG 650) is a potent, orally active kinesin-like protein KIF18A inhibitor with an IC₅₀ value of 0.071 μM. Sovilnesib can be used for the research of cancer .

HY-145803

KIF18A-IN-3	Microtubule/Tubulin	Cancer
KIF18A-IN-3 is a potent KIF18A inhibitor (IC₅₀=61 nM). KIF18A-IN-3 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-3 can be used for researching cancer .

HY-145802

KIF18A-IN-2	Microtubule/Tubulin	Cancer
KIF18A-IN-2 is a potent KIF18A inhibitor (IC₅₀=28 nM). KIF18A-IN-2 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-2 can be used for researching cancer .

HY-151879

Tubulin inhibitor 30	Microtubule/Tubulin Ferroptosis	Cancer
Tubulin inhibitor 30 (Compound 15) is a tubulin assembly inhibitor with an IC₅₀ of 0.52 μM. Tubulin inhibitor 30 can induce ferroptosis .

HY-P99593

Sofituzumab vedotin DMUC5754A	Antibody-Drug Conjugates (ADCs)	Cancer
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer .

HY-P99593A

Sofituzumab vedotin (solution) DMUC5754A (solution)	Antibody-Drug Conjugates (ADCs)	Cancer
Sofituzumab vedotin (DMUC5754A) (solution) is an antibody-drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-cleavable linker .

HY-145827

KIF18A-IN-4	Microtubule/Tubulin	Cancer
KIF18A-IN-4 is a moderately potent ATP and microtubule (MT) noncompetitive KIF18A inhibitor (IC₅₀=6.16 μM). KIF18A-IN-4 has selectivity against a large panel of mitotic kinesins and kinases, and does not show any direct effects on tubulin assembly. KIF18A-IN-4 exhibits anti-tumor activity .

HY-129932

Pyrrolidine ricinoleamide	Others	Cancer
Pyrrolidine ricinoleamide ((R)-5d) is a fatty acid amide that exhibits effective antiproliferative activity against a series of cancer cells, including human glioma U251 cells. Pyrrolidine ricinoleamide can be used in cancer research .

HY-157137

PARP1-IN-17	PARP Caspase Apoptosis	Cancer
PARP1-IN-17 is a PARP-1 inhibitor (IC₅₀ = 19.24 nM for PARP-1 and = 32.58 nM for PARP-2) and induce apoptosis. PARP1-IN-17 shows excellent anti-proliferative activity .

HY-N3446

IVHD-valtrate	Apoptosis	Cancer
IVHD-valtrate, an active Valeriana jatamansi derivative, is against human ovarian cancer cells in vitro and in vivo. IVHD-valtrate induces cancer cells apoptosis and arrests the ovarian cancer cells in the G2/M phase. IVHD-valtrate has the potential to be a novel chemotherapeutic agent for the human ovarian cancer research .

HY-146432

Antitumor agent-60	Apoptosis Raf Ras ROS Kinase MDM-2/p53
Antitumor agent-60 (compound 20) is a potent antitumor agent, targeting RAS-RAF signaling pathway and binding to CRAF with a K_d value of 3.93 μM. Antitumor agent-60 induces apoptosis by blocking cell cycle at G2/M phase. Antitumor agent-60 enhances the level of p53 and ROS. Antitumor agent-60 causes oval and irregular nucleus in cancer cells. Antitumor agent-60 can suppress the growth of tumor to some extent in A549 xenograft model .

HY-109583

4-Oxofenretinide 4-Oxo-4-HPR	Apoptosis Reactive Oxygen Species Drug Metabolite	Cancer
4-Oxofenretinide (4-Oxo-4-HPR) is a metabolite of Fenretinide (HY-15373). 4-Oxofenretinide induces cell growth inhibition in ovarian, breast, and neuroblastoma tumor cell lines. 4-Oxofenretinide causes a marked accumulation of cells in G2-M. 4-Oxofenretinide induces cancer cell apoptosis through caspase-9 .

Cat. No.	Product Name	Target	Research Area

HY-P5098

E(c(RGDfK))2	Peptides	Cancer
E(c(RGDfK)) is an αvβ3 integrin-specific binding moiety with tumor targeting properties. Increased uptake of E(c(RGDfK)) in human ovarian cancer OVCAR-3 xenograft tumors may be useful in cancer research .

Cat. No.	Product Name	Target	Research Area

HY-P99593

Sofituzumab vedotin DMUC5754A	Antibody-Drug Conjugates (ADCs)	Cancer
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer .

HY-P99593A

Sofituzumab vedotin (solution) DMUC5754A (solution)	Antibody-Drug Conjugates (ADCs)	Cancer
Sofituzumab vedotin (DMUC5754A) (solution) is an antibody-drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-cleavable linker .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N3558

Ceanothic acid Emmolic acid	Other Terpenoids other families Classification of Application Fields Terpenoids Source classification Plants Disease Research Fields Cancer	Others
Ceanothic acid (Emmolic acid) is a ring-A homologue of betulinic acid. Ceanothic acid inhibits OVCAR-3, HeLa, and FS-5 cells with the cell survival of 68%, 65%, and 81%, respectively .

HY-N7760

Neosalvianen	Structural Classification Alkaloids Terpenoids Other Alkaloids Labiatae Source classification Samanea saman (Jacq.) Merr. Diterpenoids Plants	Others
Neosalvianen is a N-containing compound that shows cytotoxic activities against the HeLa, HepG2, and OVCAR-3 cell lines, with IC₅₀ of 63.9 µM, 59.2 µM, and 74.6 µM, respectively .

HY-N10268

3-Hydroxyterphenyllin NSC 299113	Microorganisms Classification of Application Fields Source classification Phenols Polyphenols Disease Research Fields Cancer	Apoptosis
3-Hydroxyterphenyllin is a metabolite of Aspergillus candidus.3-Hydroxyterphenyllin suppresses proliferation and causes cytotoxicity against A2780/CP70 and OVCAR-3 cells. 3-Hydroxyterphenyllin induces S phase arrest and apoptosis. 3-Hydroxyterphenyllin has the potential for the research of ovarian cancer .

HY-N10922

(3S,4aS,10aS)-3-(Acetyloxy)-2,3,4,4a,10,10a-hexahydro-6-hydroxy-1,1,4a-trimethyl-7-(1-methylethyl)-9(1H)-phenanthrenone	Structural Classification Terpenoids Source classification Celastraceae Diterpenoids Celastrus Plants	Others
(3S,4aS,10aS)-3-(Acetyloxy)-2,3,4,4a,10,10a-hexahydro-6-hydroxy-1,1,4a-trimethyl-7-(1-methylethyl)-9(1H)-phenanthrenone (compound 3), a Palmitate, can be isolated from the root tissue of Salvia miltiorrhiza. (3S,4aS,10aS)-3-(Acetyloxy)-2,3,4,4a,10,10a-hexahydro-6-hydroxy-1,1,4a-trimethyl-7-(1-methylethyl)-9(1H)-phenanthrenone (compound 3) shows anti-cancer activity against human cancer cell lines with DC₅₀s of 25.5 μg/mL (HeLa), 37.5 μg/mL (HepG2), 30.2 μg/mL (OVCAR-3), respectively .

HY-N3446

IVHD-valtrate	Natural Products Classification of Application Fields Source classification Valeriana officinalis Linn. Plants Valerianaceae Disease Research Fields Cancer	Apoptosis
IVHD-valtrate, an active Valeriana jatamansi derivative, is against human ovarian cancer cells in vitro and in vivo. IVHD-valtrate induces cancer cells apoptosis and arrests the ovarian cancer cells in the G2/M phase. IVHD-valtrate has the potential to be a novel chemotherapeutic agent for the human ovarian cancer research .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Name
Email *

	Sorry, but the email address you supplied was invalid.

OVCaR-3

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Natural
Products